1. Zhou LF, Zhang MS, Hu AH, et al.Selective blockade of NF-κB by novel mutated IκBαsuppresses CD3/CD28-induced activation of memory CD4+ T cells in asthma.Allergy, 2008, 63:509-517.
5. Busse W, Corren J, Lanier BQ, et al.Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.J Allergy Clin Immunol, 2001, 108:184-190.
[4]
6. Bousquet J, Wenzel S, Holgate S, et al.Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma.Chest, 2004, 125:1378-1386.
[5]
7. Buhl R, Soler M, Matz J, et al.Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma.Eur Respir J, 2002, 20:73-78.
[6]
9. Humbert M, Beasley R, Ayres J, et al.Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment):INNOVATE.Allergy, 2005, 60:309-316.
[7]
10. Ayres JG, Higgins B, Chilvers ER, et al.Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.Allergy, 2004, 59:701-708.
[8]
16. Korn S, Thielen A, Seyfried S, et al.Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.Respir Med, 2009, 103:1725-1731.
[9]
19. Busse WW, Wayne J.Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.N Engl J Med, 2011, 364:1005-1015.
[10]
3. Jadad AR, Moore RA, Carroll D, et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary? Control Clin Trials, 1996, 17:1-12.
[11]
4. Soler M, Matz J, Townley R, et al.The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.Eur Respir J, 2001, 18:254-261.
[12]
8. Holgate ST, Chuchalin AG, Hébert J, et al.Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.Clin Exp Allergy, 2004, 34:632-638.
[13]
11. Vignola AM, Humbert M, Bousquet J, et al.Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis:SOLAR.Allergy, 2004, 59:709-717.
[14]
12. Ohta K, Miyamoto T, Amagasaki T, et al.Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.Respirology, 2009, 14:1156-1165.
[15]
13. Hanania NA, Alpan O, Hamilos DL, et al.Omalizumab in severe allergic asthma inadequately controlled with standard therapy.Ann Intern Med, 2011, 154:573-582.
17. Hitt E.Omalizumab improves asthma control in inner-city children.N Engl J Med, 2011, 364:1005-1015.
[19]
18. Wahn U, Martin C, Freeman P, et al.Relationship between pretreatment specific IgE and the response to omalizumab therapy.Allergy, 2009, 64:1780-1787.
[20]
20. FDA says asthma drug Xolair raises risk of heart, brain problems.Reuters.2014-0926.http://www.reuters.com/article/2014/09/26/us-roche-xolair-safety-idUSKCN0HL2EN20140926.
